BioWorld

Jan. 23, 2004

Bringing In IL13 Phase III Trial Support, NeoPharm Gets $68.4M

NeoPharm Inc. intends to use proceeds from a $68.4 million public offering to advance its cancer agent for malignant glioma. (BioWorld Today) Read More

Genaera Gains $20M Through Direct Stock Equity Placement

Childhood Brain Tumor Growth With Neurofibromatosis Needs Abnormal Cellular Neighbors In Mouse Model

NIH Director In Senate Hot Seat Over Employee Disclosure Rules

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

Illustration of motor neuron connecting to muscle fiber

Research grants support early clinical trials of ALS treatments

BioWorld Science

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...